Natriuretic peptides for the detection of paroxysmal atrial fibrillation by Seegers, Joachim et al.
Natriuretic peptides for the detection
of paroxysmal atrial ﬁbrillation
Joachim Seegers,1,2 Markus Zabel,1 Timo Grüter,1 Antje Ammermann,3
Mark Weber-Krüger,1 Frank Edelmann,1,4,5,6 Götz Gelbrich,7 Lutz Binder,8
Christoph Herrmann-Lingen,4,9 Klaus Gröschel,10 Gerd Hasenfuß,1,4
Nicolas Feltgen,3 Burkert Pieske,5,6 Rolf Wachter1,4
To cite: Seegers J, Zabel M,
Grüter T, et al. Natriuretic
peptides for the detection
of paroxysmal atrial
fibrillation. Open Heart
2015;2:e000182.
doi:10.1136/openhrt-2014-
000182
Received 8 August 2014
Revised 18 November 2014
Accepted 20 January 2015
For numbered affiliations see
end of article.
Correspondence to
Dr Rolf Wachter;
Wachter@med.uni-
goettingen.de
ABSTRACT
Background and purpose: Silent atrial fibrillation
(AF) and tachycardia (AT) are considered precursors of
ischaemic stroke. Therefore, detection of paroxysmal
atrial rhythm disorders is highly relevant, but is
clinically challenging. We aimed to evaluate the
diagnostic value of natriuretic peptide levels in the
detection of paroxysmal AT/AF in a pilot study.
Methods: Natriuretic peptide levels were analysed in
two independent patient cohorts (162 patients with
arterial hypertension or other cardiovascular risk
factors and 82 patients with retinal vessel disease). N-
terminal-pro-brain natriuretic peptide (NT-proBNP) and
BNP were measured before the start of a 7-day Holter
monitoring period carefully screened for AT/AF.
Results: 244 patients were included; 16 had
paroxysmal AT/AF. After excluding patients with a
history of AT/AF (n=5), 14 patients had newly
diagnosed AT/AF (5.8%) NT-proBNP and BNP levels
were higher in patients with paroxysmal AT/AF in both
cohorts: (1) 154.4 (IQR 41.7; 303.6) versus 52.8
(30.4; 178.0) pg/mL and 70.0 (31.9; 142.4) versus
43.9 (16.3; 95.2) and (2) 216.9 (201.4; 277.1) versus
90.8 (42.3–141.7) and 96.0 (54.7; 108.2) versus 29.1
(12.0; 58.1). For the detection of AT/AF episodes, NT-
proBNP and BNP had an area under the curve in
receiver operating characteristic analysis of 0.76 (95%
CI, 0.64 to 0.88; p=0.002) and 0.75 (0.61 to 0.89;
p=0.004), respectively.
Conclusions: NT-proBNP and BNP levels are elevated
in patients with silent AT/AF as compared with sinus
rhythm. Thus, screening for undiagnosed paroxysmal
AF using natriuretic peptide level initiated Holter
monitoring may be a useful strategy in prevention of
stroke or systemic embolism.
INTRODUCTION
Atrial ﬁbrillation (AF) is an established risk
factor for ischaemic stroke.1 A meta-analysis
indicates that oral anticoagulation therapy
with warfarin reduces stroke risk by 64% on
an intention to treat basis.2 Identifying par-
oxysmal AF may be challenging in patients
presenting with sinus rhythm, especially as
episodes of AF may not be symptom related,3
but the risk for thromboembolism is similar
to that for permanent AF.4 Prolonged,5 6 or
continuous,7 rhythm monitoring may
enhance the detection of this clinically
‘silent’ paroxysmal AF. Although such
extended diagnostics have been performed
in a large number of patients,8 this seems to
be not feasible for clinical routine as they are
uncomfortable for the patient and time-
consuming. Investigation on natriuretic pep-
tides has shown their potential to predict AF
within the general population,9 as well as in
patients undergoing surgical procedures.10
Moreover, elevation of natriuretic peptide
levels was shown in patients suffering from
AF,11 12 which decreases after conversion to
sinus rhythm.13 14 Recently, we have shown
that the brain natriuretic peptide (BNP) is
KEY MESSAGES
What is already known about this subject?
The early detection of paroxysmal atrial fibrillation
(AF) is a very attractive strategy for primary stroke
prevention. Extensive Holter monitoring up to
7 days is useful to detect AF, but it is not feasible to
screen the whole population.
How might this impact on clinical practice?
A biomarker screening to decide whether or not to
perform extended Holter monitoring for the first
detection on AF may reduce the number of patients
to be screened by Holter. Once AF is detected,
>90% of patients need oral anticoagulants for
primary stroke prevention. Biomarker level-guided
indication of Holter ECG may be an attractive strat-
egy for AF detection and thus primary stroke
prevention.
What does this study add?
Brain natriuretic peptide and N-terminal-pro-BNP
values in patients with paroxysmal AF were signifi-
cantly higher and showed very good diagnostic
properties for AF detection. Therefore, these
markers may be very useful for identifying patients
with otherwise undetected AF.
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an independent predictor of paroxysmal AF detected by
prolonged ECG monitoring in patients with cerebral
ischaemia (secondary stroke prevention),15 Thus, we
hypothesised that natriuretic peptide levels may also
help to identify AF in patients with cardiovascular risk
factors as a potential prevention strategy and aimed to
evaluate the diagnostic value in a pilot study.
MATERIALS AND METHODS
Patients
Patients participating in this observational trial were
recruited from the collective of the ongoing non-
interventional diastolic congestive heart failure
(Diast-CHF) trial, which is part of the nationwide
German Competence Network Heart Failure. Inclusion
and exclusion criteria have been described previously.16
Brieﬂy, a total of 1735 patients with at least one risk
factor for heart failure with preserved left ventricular
function (deﬁned as history of hypertension, diabetes
mellitus, sleep apnoea syndrome or atherosclerotic
disease) or established CHF were referred by a network
of primary care physicians between 2004 and 2006. After
the baseline visit which included N-terminal-pro-brain
natriuretic peptide (NT-proBNP) analysis, NT-proBNP
values were divided into quartiles. Only patients with
NT-proBNP in the lowest (NT-proBNP<53 pg/mL) and
in the highest NT-proBNP-quartile (NT-proBNP
>226 pg/mL) at the baseline visit presenting with sinus
rhythm in the 12-lead ECG and without an implanted
cardiac device were selected and randomly asked to par-
ticipate in this substudy which was part of the 1 year
follow-up examination of the patients. Patient selection
and all clinical examinations were performed by investi-
gators blinded to NT-proBNP values and quartiles. As
systolic dysfunction (ejection fraction<50%) is a known
cause of elevated natriuretic peptide levels, these
patients were excluded. Diast-CHF complies with the
Declaration of Helsinki; the protocol was approved by
the responsible ethics committee and all patients gave
written informed consent. The recruitment process of
the Diast-CHF substudy is shown in ﬁgure 1.
In addition, a second cohort was added using data
from patients enrolled in the Find-AF eye study. In brief,
Find-AF eye is a single centre study and consecutively
enrolled 101 patients with retinal artery occlusion or
venous retinal thrombosis. Only patients free of AF on
admission ECG and with an evaluable 7-day Holter ECG
were included in the analysis of this manuscript (n=82).
Data collection and clinical evaluation
All patients underwent medical history, physical examin-
ation, a 12-lead ECG and standard echocardiography at
baseline.
Blood analysis
Blood samples were drawn immediately before Holter
ECG was started and were stored at −80°C for later
analysis. Plasma levels of NT-proBNP were measured
using a sandwich immunoassay (Roche Diagnostics,
Mannheim, Germany). BNP was measured by means of
a sandwich immunoassay (Abbott GmbH & Co. KG,
Wiesbaden, Germany). N-terminal pro atrial natriuretic
peptide (NT-proANP) was measured by using a sandwich
immunoassay (Biomedica Medizinprodukte, Vienna,
Austria). Personnel responsible for the determination of
natriuretic peptide levels were blinded to clinical patient
data.
Holter ECG
A dual-channel Holter ECG was recorded with digital
portable recorders (Diast-CHF: Lifecard CF, Del Mar
Reynolds Medical Ltd, Hertford, UK, and Find-AF eye:
getemed, Teltow, Germany) for seven consecutive days.
Analysis was performed with Pathﬁnder digital (Software
Version V8.602, Del Mar Reynolds Medical Ltd) or
Cardioday (getemed). Episodes with sudden rapid
changes in heart rate or sudden onset of arrhythmia in
the manual review of the Holter ECG were carefully ana-
lysed for AF and atrial ﬂutter (atrial tachycardia, AT).
AT/AF was diagnosed if episodes lasted more than 30 s.
Figure 1 Flow chart of the recruitment process (diastolic
congestive heart failure, Diast-CHF; NT-proBNP,
N-terminal-pro-brain natriuretic peptide).
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Equivocal ﬁndings were cograded by an additional phys-
ician blinded to the data.
Definition of primary end point
The primary hypothesis was that higher natriuretic
peptide levels can discriminate patients with paroxysmal
AT/AF from those without AT/AF. We measured both
NT-proBNP and BNP (which is measured in many insti-
tutions instead of NT-proBNP).
Statistical analyses
Continuous data are shown as mean±SD. Values of natri-
uretic peptides were not normally distributed and are
therefore given as median and IQR of 25th and 75th
centile. Categorical variables are given as absolute
numbers (percentage). Receiver operating characteristic
(ROC) curves were used to describe test characteristics.
Statistical tests were performed with SPSS Statistics 21.0
(IBM, Chicago, Illinois, USA). A p value below 0.05 was
considered to be signiﬁcant.
RESULTS
Study population
Of the patients included in the Diast-CHF trial, a total of
615 patients were eligible in principle; the number of
Holter recorder systems and the analysis time available
was the most relevant restriction to patient recruitment.
Of the 200 patients asked to participate, 167 provided
written informed consent. Five patients were excluded
for technical problems during the Holter recording
(ﬁgure 1). Of the remaining 162 patients, 156 (96%)
had 7 days of recording, whereas the other 6 patients
had at least 4 days of recording. The Find-AF eye cohort
consisted of 82 patients with an evaluable 7 day Holter
ECG.
The baseline characteristics of the 162 patients of the
Diast-CHF substudy and the additional 82 patients taken
from the Find-AF eye study are displayed in table 1. Five
(2%) patients with a history of AF in the Diast-CHF
cohort were excluded for further analysis. In both
cohorts combined, 14 (5.8%) patients had AT/AF for at
least 30 s during Holter monitoring (table 2). Median
duration (IQR) of AT/AF was 24.5 (3.3–1046.8) min,
and eight patients had an episode of at least 6 min
(ASSERT criteria).17
Natriuretic peptides and paroxysmal AF
Table 3 shows the median and IQR of BNP and
NT-proBNP levels. NT-proANP was only measured in
Find-AF eye. Plasma levels of natriuretic peptides were
numerically higher in paroxysmal AT/AF patients in
both cohorts.
Diagnostic utility of natriuretic peptides
For ROC analysis, data of both cohorts were pooled to
determine the diagnostic utility of natriuretic peptides
for the detection of paroxysmal AT/AF. Figure 2 shows
the ROC curves for BNP and NT-proBNP; area under
curve was 0.75 (95% CI, 0.61 to 0.89; p=0.004) and 0.76
(95% CI, 0.64 to 0.88; p=0.002), respectively.
Clinical relevance
The ﬁnding of paroxysmal AF in our study was of clin-
ical relevance. In 13 of the 14 patients, the detection of
paroxysmal AF would have led to a change in antithrom-
botic therapy according to recent guidelines18 (from no
therapy to oral anticoagulation in 5 patients and from
aspirin to oral anticoagulation in 8 patients).
DISCUSSION
The major ﬁnding of this study is that natriuretic
peptide plasma levels are higher in patients suffering
from paroxysmal AT/AF compared with those without
AT/AF in two different independent cohorts. Although
natriuretic peptides are mainly used for the diagnosis of
heart failure,19 they are also elevated in a number of dif-
ferent diseases (eg, asymptomatic systolic and diastolic
dysfunction,20 pulmonary embolism21 and other
diseases).
In addition, natriuretic peptides have also been shown
to be elevated in patients with AF as compared to
patients with sinus rhythm,14 Moreover, natriuretic pep-
tides have been shown to predict future AF in several
clinical settings,9 22 Pathophysiological, increased
haemodynamic load causes atrial stretch, which is well
known as a reason for development of AT/AF.23
Natriuretic peptides correlate with haemodynamic
load;19 thus, their indicative value for diagnosis of
unknown AT/AF may be equal or superior to clinical
risk factors of AF.
Recently, we showed that natriuretic peptides are ele-
vated in patients with stroke with undiagnosed paroxys-
mal AF as compared with sinus rhythm.15 We now
extend these ﬁndings to two different clinical settings:
patients with risk factors for heart failure and patients
with retinal vessel occlusion.
The clinical relevance of early detection of the
so-called ‘silent AT/AF’ was recently underlined by the
ASSERT study which revealed that patients with short
episodes of AF (>6 min within 3 months) have a 2.5-fold
increase in the risk of stroke and systemic embolism.17
The early detection of subclinical AF in patients at risk
for AF is a major challenge and potentially a very effect-
ive stroke prevention strategy.17 24 Recently, a stepwise
screening approach was reported in elderly patients to
identify (asymptomatic) paroxysmal AF. During a 2-week
recording of 20–30 s two times per day using a hand-
held ECG in 75-year-old patients without a history of AF,
paroxysmal AT/AF was identiﬁed in only 4%, indicating
that a large number of patients have to be screened to
diagnose one patient with paroxysmal AT/AF.8
Natriuretic peptides were not used in this study for pre-
selecting study participants. In daily life, risk of AT/AF
development are commonly determined ﬁrst by clinical
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risk factors (eg, age) followed by a standard 12-lead
ECG. However, these workups will identify a small
number of patients with ‘silent’ AT/AF.8 25 Thus, if AT/
AF is assumed but not diagnosed, identifying those
patients with an increased risk of paroxysmal AT/AF
using natriuretic peptides seems highly attractive.
Table 1 Patient characteristics
DIAST-CHF Find-AF eye
No paroxysmal
AT/AF (n=152)
Paroxysmal
AT/AF (n=10)
No paroxysmal
AT/AF (n=76)
Paroxysmal
AT/AF (n=6)
Age (years) 64±7 66±7 63±11 77±6
Male gender (%) 90 (59) 6 (60) 48 (63) 4 (67)
BMI (kg/m²) 28.8±4.4 32.4±4.0 28.2±5.5 28.8±6.2
Heart rate (bpm) 72±14 71±13 76±14 68±15
Systolic blood pressure (mm Hg) 147±20 148±19 152±27 127±9
Diastolic blood pressure (mm Hg) 84±12 82±11 88±17 71±8
Laboratory
Creatine (mg/dL) 1.0±0.3 0.9±0.2 1.0±0.4 1.4±0.7
Haemoglobin (mg/dL) 14.2±1.2 13.8±1.1 14.2±1.4 14.2±1.6
Thyroid-stimulating hormone (iU/mL) 1.53±5.92 1.67±0.80 1.39±0.83 1.27±0.60
ECG
PQ interval (ms) 168±26 180±31 166±30 185±39
QRS duration (ms) 92±13 97±12 91±14 104±17
QT interval (ms) 389±33 403±30 379±31 407±29
Echo
Left atrial diameter (mm) 41±5 46±4 42±4 47±6
Tissue Doppler a’-wave (cm/s) 11.0±2.5 9.7±2.1 10.8±2.1 3.6±0.4
Left ventricular ejection fraction (%) 60±7 60±8 64±9 64±8
Left ventricular mass index (g/m²) 117±24 128±23 94±27 120±52
Co-disease
Hypertension (%) 140 (92) 8 (80) 37 (49) 5 (83)
Diabetes (%) 42 (28) 3 (30) 9 (12) 3 (50)
Smoker (%) 82 (54) 3 (30) 46 (61) 3 (50)
Hyperlipidaemia (%) 71 (47) 5 (50) 16 (21) 4 (67)
Coronary artery disease (%) 32 (21) 2 (20) 6 (8) 2 (33)
History of AF (%) 3 (2) 2 (20) 0 (0) 0 (0)
Prior stroke (%) 5 (3) 2 (20) 2 (3) 0 (0)
CHA2DS2VASc Score (median (IQR)) 3 (2;3) 3 (1;4) 2 (1;2) 4 (4;4)
AF, atrial fibrillation; AT, atrial tachycardia; BMI, body mass index; DIAST-CHF, diastolic congestive heart failure.
Table 2 AT/AF burden, prior antithrombotic therapy and CHA2DS2-VASc Score
28 of the 14 patients with AT/AF detected by
prolonged Holter monitoring
Episodes
(n)
Cumulative
time of
AT/AF (min)
Type of
arrhythmia
At least
1 episode
>6 min
Antithrombotic/
antiplatelet
therapy
CHA2DS2-VASc
score
Diast-CHF #2 3 2 AT No None 1
Diast-CHF #4 1 2 AF No ASA 4
Diast-CHF #5 4 7 AT No None 2
Diast-CHF #6 1 1066 AF Yes ASA 8
Diast-CHF #7 2 36 AT Yes ASA 2
Diast-CHF #8 3 1160 AF Yes None 1
Diast-CHF #9 2 9 AF No None 1
Diast-CHF #10 2 13 AT Yes ASA 5
Find-AF eye #1 NA 1 AF No ASA 2
Find-AF eye #2 NA 1 AF No None 4
Find-AF eye #3 NA >1440 AF Yes OAC 4
Find-AF eye #4 NA >1440 AF Yes ASA 4
Find-AF eye #5 NA 989 AF Yes ASA 4
Find-AF eye #6 NA 215 AF Yes ASA 3
AF, atrial fibrillation; ASA, acetylsalicylic acid; AT, atrial tachycardia; CHA2DS2-VASc, congestive heart failure, hypertension, age≥75
(doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); NA, not applicable; OAC, oral anticoagulation.
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Strengths and limitations
Our study is strengthened by its use and detailed analysis
of a continuous 7-day Holter ECG for the evaluation of
paroxysmal AF/AT allowed detecting a high number of
affected patients, which is higher than that diagnosed by
periodic ECGs and cardiac event loop recorders,26 and
similar ﬁndings in two different independent cohorts.
Our ﬁndings are in line with our prior study in a third
cohort.15 However, the sample size was too small to
perform a detailed analysis on the independence of the
indicative value of natriuretic peptide plasma levels for
paroxysmal AT/AF, and the indicative value of BNP
found in the present analysis has to be validated in
larger trials. Furthermore, we cannot exclude that more
intensive monitoring (eg, by an implantable loop
recorder) would have detected a larger number of
patients with paroxysmal AF. However, the initial selec-
tion of patients with Diast-CHF, which was performed by
the lowest and highest quartiles of the baseline
NT-proBNP plasma level of the Diast-CHF trial during
the baseline visit, may cause an overestimation of the dis-
criminatory value.
The amount of paroxysmal AF which leads to an
increase in stroke risk is not known. Although there is
now some evidence that patients with episodes lasting
longer than 6 min are at increased risk (ASSERT),17 the
risk of stroke may already be elevated in patients with
excessive supraventricular ectopic activity.27 Otherwise, it
is not known whether the risk in these patient popula-
tions is similar to that in patients with permanent AF
and whether these patients beneﬁt similarly from oral
anticoagulation.
CONCLUSION
In two independent patient cohorts, natriuretic peptide
levels were higher in patients with AF/AT as compared
to patients with sinus rhythm. It may therefore be worth-
while to further evaluate the utility of natriuretic pep-
tides in identifying patients at risk for AF/AT to be
chosen for further workup (eg, prolonged Holter moni-
toring) as a tool for stroke prevention.
Author affiliations
1Department of Cardiology and Pneumology, University of Göttingen,
Göttingen, Germany
2Department of Internal Medicine II—Cardiology, University Hospital
Regensburg, Regensburg, Germany
3Department of Ophthalmology, University of Göttingen, Göttingen, Germany
4German Cardiovascular Research Center (DZHK), Göttingen, Germany
5Department of Internal Medicine, Cardiology, Charité – Campus Virchow-
Klinikum, Universitätsmedizin Berlin, Berlin, Germany
6German Cardiovascular Research Center (DZHK), partner site Berlin,
Germany
7Institute for Clinical Epidemiology and Biometry, University of Würzburg,
Würzburg, Germany
8Department of Clinical Chemistry, University of Göttingen, Göttingen,
Germany
9Department of Psychosomatic Medicine and Psychotherapy, University of
Göttingen, Göttingen, Germany
10Department of Neurology, Mainz University Medical Center, Mainz, Germany
Contributors JS and RW wrote the paper. TG collected the data. MZ, AA,
MW-K, FE, LB, LB, CH-L, KG, GH, NF and BP provided significant input and
improvement of the whole paper. GG performed statistical analysis.
Table 3 Natriuretic peptide plasma levels in patients with and without paroxysmal AT/AF (5 patients with a history of AF
were excluded from the analysis)
No paroxysmal AT/AF Paroxysmal AT/AF
Diast-CHF n=149 n=8
NT-proBNP (pg/mL) 52.8 (30.4–178.0) 154.4 (41.7–303.6)
BNP (pg/mL) 43.9 (16.3–95.2) 70.0 (31.9–142.4)
Find-AF eye n=76 n=6
NT-proBNP (pg/mL) 90.8 (42.3–141.7) 216.9 (201.4–277.1)
BNP (pg/mL) 29.1 (12.0–58.1) 96.0 (54.7–108.2)
NT-proANP (nmol/L) 1.8 (1.0–2.7) 4.4 (4.3–4.4)
All data are displayed as median (25th-75th centile).
AF, atrial fibrillation; AT, atrial tachycardia; BNP, brain natriuretic peptide; NT-proANP, N-terminal pro-atrial natriuretic peptide, NT-proBNP,
N-terminal pro-BNP.
Figure 2 Receiver operating characteristics curve of
N-terminal pro-atrial natriuretic peptide plasma levels (dark
line) and brain natriuretic peptide (dashed line) for the
detection of paroxysmal atrial tachycardia and atrial
fibrillation.
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